Search

Supplemental material, sj-docx-3-tan-10.1177_17562864221114357 for Chinese guideline on the application of anti-seizure medications in the perioperative period of supratentorial craniocerebral surgery by Shuli Liang, Xing Fan, Feng Chen, Yonghong Liu, Binghui Qiu, Kai Zhang, Songtao Qi, Guojun Zhang, Jinfang Liu, Jianguo Zhang, Jun Wang, Xiu Wang, Ziyang Song, Guoming Luan, Xuejun Yang, Rongcai Jiang, Hua Zhang, Lei Wang, Yongping You, Kai Shu, Xiaojie Lu, Guoyi Gao, Bo Zhang, Jian Zhou, Hai Jin, Kaiwei Han, Yiming Li, Junji Wei, Kun Yang, Gan You, Hongming Ji, Yuwu Jiang, Yi Wang, Zhiguo Lin, Yan Li, Xuewu Liu, Jie Hu, Junming Zhu, Wenling Li, Yongxin Wang, Dezhi Kang, Hua Feng, Tinghong Liu, Xin Chen, Yawen Pan, Zhixiong Liu, Gang Li, Yunqian Li, Ming Ge, Xianming Fu, Yuping Wang, Dong Zhou, Shichuo Li, Tao Jiang, Lijun Hou and Zhen Hong in Therapeutic Advances in Neurological Disorders

Supplemental material, sj-docx-2-tan-10.1177_17562864221114357 for Chinese guideline on the application of anti-seizure medications in the perioperative period of supratentorial craniocerebral surgery by Shuli Liang, Xing Fan, Feng Chen, Yonghong Liu, Binghui Qiu, Kai Zhang, Songtao Qi, Guojun Zhang, Jinfang Liu, Jianguo Zhang, Jun Wang, Xiu Wang, Ziyang Song, Guoming Luan, Xuejun Yang, Rongcai Jiang, Hua Zhang, Lei Wang, Yongping You, Kai Shu, Xiaojie Lu, Guoyi Gao, Bo Zhang, Jian Zhou, Hai Jin, Kaiwei Han, Yiming Li, Junji Wei, Kun Yang, Gan You, Hongming Ji, Yuwu Jiang, Yi Wang, Zhiguo Lin, Yan Li, Xuewu Liu, Jie Hu, Junming Zhu, Wenling Li, Yongxin Wang, Dezhi Kang, Hua Feng, Tinghong Liu, Xin Chen, Yawen Pan, Zhixiong Liu, Gang Li, Yunqian Li, Ming Ge, Xianming Fu, Yuping Wang, Dong Zhou, Shichuo Li, Tao Jiang, Lijun Hou and Zhen Hong in Therapeutic Advances in Neurological Disorders

Supplemental material, sj-docx-1-tan-10.1177_17562864221114357 for Chinese guideline on the application of anti-seizure medications in the perioperative period of supratentorial craniocerebral surgery by Shuli Liang, Xing Fan, Feng Chen, Yonghong Liu, Binghui Qiu, Kai Zhang, Songtao Qi, Guojun Zhang, Jinfang Liu, Jianguo Zhang, Jun Wang, Xiu Wang, Ziyang Song, Guoming Luan, Xuejun Yang, Rongcai Jiang, Hua Zhang, Lei Wang, Yongping You, Kai Shu, Xiaojie Lu, Guoyi Gao, Bo Zhang, Jian Zhou, Hai Jin, Kaiwei Han, Yiming Li, Junji Wei, Kun Yang, Gan You, Hongming Ji, Yuwu Jiang, Yi Wang, Zhiguo Lin, Yan Li, Xuewu Liu, Jie Hu, Junming Zhu, Wenling Li, Yongxin Wang, Dezhi Kang, Hua Feng, Tinghong Liu, Xin Chen, Yawen Pan, Zhixiong Liu, Gang Li, Yunqian Li, Ming Ge, Xianming Fu, Yuping Wang, Dong Zhou, Shichuo Li, Tao Jiang, Lijun Hou and Zhen Hong in Therapeutic Advances in Neurological Disorders

Traumatic brain injury (TBI), a mainly lethal and highly debilitating condition, is increasing worldwide. However, the underlying mechanism has not been fully elucidated and effective therapy is needed. Long noncoding RNAs (lncRNAs), which form a major class of noncoding RNAs, have emerged as novel targets for regulating physiological functions and mediating numerous neurological diseases. Notably, gene expression profile analyses have demonstrated aberrant changes in lncRNA expression in the cerebral cortex and hippocampus of rats, mice and human after TBI. lncRNAs may be associated with multiple pathophysiological processes following TBI and might play a crucial role in complications of TBI, such as traumatic optic neuropathy due to the regulation of specific signaling pathways. Some lncRNAs have also been found to be therapeutic targets for motor and cognitive recovery after TBI. lncRNAs may be promising biomarkers for TBI diagnosis, treatment, and prognosis prediction. However, further research isneeded to clarify the underlying mechanisms and therapeutic effects of lncRNAs on TBI. We review the current progress of studies on lncRNAs in TBI to draw more attention to their roles in this debilitating condition., Video abstract Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/2G17m4oyiwg

// Danfeng Zhang 1 * , Jigang Chen 1 * , Zhenxing Li 1 * , Junyu Wang 1 , Kaiwei Han 1 and Lijun Hou 1 1 Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China * These authors contributed equally to this work Correspondence to: Lijun Hou, email: lijunhoucz@126.com Kaiwei Han, email: toi@163.com Junyu Wang, email: jerome2008@163.com Keywords: nonfunctioning giant pituitary adenomas; hydrocephalus; clinical features; management; surgical approach Received: July 31, 2017 Accepted: December 05, 2017 Epub: January 11, 2018 Published: March 16, 2018 ABSTRACT We evaluated the features of clinically nonfunctioning giant pituitary adenomas (NFGPAs) causing hydrocephalus to highlight the timing of hydrocephalus management and surgical approaches. A total of 24 patients with NFGPAs and hydrocephalus were included. Eighteen patients underwent endoscopic transsphenoidal surgery. Ten patients received pterional surgery, including 6 patients as first treatment and 4 cases with recurrence after transsphenoidal approach. Gross total resection was achieved in 10 patients, including 6 cases (6/18, 33.3%) with endoscopic transsphenoidal surgery and 4 cases (4/10, 40%) with pterional surgery. All patients were divided into preoperative EVD group and non-preopoerative EVD group. The proportion of patients receiving postoperative EVD or shunt was significantly higher in non-preoperative EVD group than that in preoperative EVD group (9/15 vs. 1/9, P = 0.033). Visual impairment score (VIS) was evaluated for each patient. We detected significant vision improvement according to the preoperative and postoperative VIS (median, interquartile range: 62, 48.25–77 vs. 36.5, 0–50.75, P < 0.001). Conclusively, for patients with NFGPAs and hydrocephalus, preoperative EVD might reduce the need for a second shunt or EVD. Surgical approach should be decided based on the clinicoradiological features and surgeons’ experience for individualized treatment, and endoscopic transsphenoidal resection of pituitary adenomas was suggested for most NFGPAs.

Purpose. Different microRNAs (miRs) have been demonstrated to relate with the outcome of glioma patients, while the conclusions are inconsistent. We perform a meta-analysis to clarify the relationship between different miRs and prognosis of glioma. Methods. Related studies were retrieved from PubMed, Embase, and Cochrane Library. Pooled hazard ratios (HRs) of different miRs expression for survival and 95% confidence intervals (CIs) were calculated using random-effects model. Results. A total of 15 miRs with 4708 glioma patients were ultimately included. Increased expression of miR-15b (HR, 1.584; 95% CI, 1.199-2.092), 21 (HR, 1.591; 95% CI, 1.278-1.981), 148a (HR, 1.122; 95% CI, 1.023-1.231), 196 (HR, 1.877; 95% CI, 1.033-3.411), 210 (HR, 1.251; 95% CI, 1.010-1.550), and 221 (HR, 1.269; 95% CI, 1.054-1.527) or decreased expression of miR-106a (HR, 0.809; 95% CI, 0.655-0.998) and 124 (HR, 0.833; 95% CI, 0.729-0.952) was correlated with poor outcome of glioma patients. Conclusions. miR-15b, 21, 148a, 196, 210, 221, 106a, and 124 are valuable biomarkers for the prognosis of glioma which might be used in clinical settings.